Literature DB >> 10664386

Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins.

A K Falconar1.   

Abstract

The protective capacity of monoclonal antibodies (MAbs) generated to the dengue-2 virus envelope (E) and premembrane (prM) proteins was tested in vivo. Two anti-E MAbs, 2C5.1 and 4G2 and two anti-prM MAbs, 2A4.1 and 2H2 provided cross-protection against all four dengue virus serotypes. Overlapping sets of synthetic peptides spanning amino-acid sequence 301-401 (domain III) of the E protein and the entire prM protein were then used to locate their epitopes. The anti-E MAbs strongly reacted with the peptide sequence 349-GRLITVNPIVT-359 (E349-359) from domain III and the immunodominant epitope, 274-SGNLLFTGHL-283 (E274-283) from the hinge region between domains I and II. The anti-prM MAbs strongly reacted with the sequence, 40-PGFTVMAAIL-49 (M40-49) from the first membrane-spanning domain of the M protein. These anti-prM MAbs also reacted with peptides E274-283 and E349-359, while the anti-E MAbs reacted with a peptide sequence, 1-FHLTTRNGEP-10 from the prM protein and these cross-reactions with both proteins were confirmed using immunoblot assays. MAbs 2C5.1, 4G2 and 2H2 more strongly reacted with an MEH1 peptide GLFTPNLITI, which was designed as an antigenic hybrid between these E and prM peptide sequences, than with any of these natural peptide sequences. These peptide sequence will now be tested for their ability to generate cross-protective antibodies against each dengue virus serotype when delivered with appropriate T-helper epitopes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10664386     DOI: 10.1007/s007050050646

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  54 in total

1.  B-cell responses during primary and secondary dengue virus infections in humans.

Authors:  Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

Review 2.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

4.  Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction.

Authors:  Jiraphan Junjhon; Matthawee Lausumpao; Sunpetchuda Supasa; Sansanee Noisakran; Adisak Songjaeng; Prakaimuk Saraithong; Kridsada Chaichoun; Utaiwan Utaipat; Poonsook Keelapang; Amornrat Kanjanahaluethai; Chunya Puttikhunt; Watchara Kasinrerk; Prida Malasit; Nopporn Sittisombut
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

Review 5.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

6.  Antibody recognition of the dengue virus proteome and implications for development of vaccines.

Authors:  Stefan Fernandez; Emily D Cisney; Alexander P Tikhonov; Barry Schweitzer; Robert J Putnak; Monika Simmons; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

Review 7.  Degrees of maturity: the complex structure and biology of flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

8.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines.

Authors:  Andrew K I Falconar
Journal:  Clin Vaccine Immunol       Date:  2007-12-26

10.  Immature dengue virus: a veiled pathogen?

Authors:  Izabela A Rodenhuis-Zybert; Hilde M van der Schaar; Júlia M da Silva Voorham; Heidi van der Ende-Metselaar; Huan-Yao Lei; Jan Wilschut; Jolanda M Smit
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.